NFκB signaling can then switch to a tumor promoting pathway as cells undergo transformation, such as the introduction of mutant RasG12V into the MEFs, by allowing the transformed cells to avoid macrophage-induced cell death and evading other antitumor immunity activities in vivo [134]. The gene discussed is NFKB1; the disease is neoplasm.